Norway to buy Biogen's Spinraza medicine -broadcaster NRK

OSLO, Feb 12 (Reuters) - Norwegian authorities will buy the rare-disease treatment Spinraza for patients from U.S. drugmaker Biogen Inc at a cost of 7 million Norwegian crowns ($880,381.33) per year per patient, public broadcaster NRK reported on Monday.